MED3000, our lead product, is a topical gel which utilises our proprietary technology DermaSys®, developed specifically for the treatment of erectile dysfunction (“ED”). MED3000 is a fast-acting topical treatment which has the potential to be a highly differentiated product by addressing significant unmet needs in the ED market.
MED3000 is a topical gel applied directly to the head (glans) of the penis for the treatment of ED.
MED3000 works through an evaporative and unique mode of action. MED3000’s combination of volatile solvent components creates an evaporative and novel action that stimulates nerve sensors in the highly innervated glans penis rapidly, leading to smooth muscle relaxation, tumescence and erection.
Futura aims to create a network of licensing and distribution partners with strength in brand building, pharmaceutical credibility and regional infrastructure and marketing expertise for long-term distribution of MED3000 across the globe. We continue to target initial launches later in 2022, although exact markets have not yet been agreed with distribution partners. Further launches are expected in in 2023.
On Friday 30th April the Company announced that it has now received its MDR EU Quality Management Certificate for the placing on the market of a Class II(b) medical device known as MED3000 (“CE mark approval”).
The approval of MED3000 from the EU Notified Body paves the way for rapid approval in many countries around the world, including in the Middle East, Africa, the Far East Latin American regions which allow “fast-track” review based on recognition of the EU CE mark. Due to post-Brexit arrangements, the EU CE mark can be used to market the product in Great Britain until 30 June 2023 by which time a specific UKCA mark has to be obtained. This will be a streamlined process since it is understood the UK application can bridge to the EU approval.
Futura has retained specialist corporate advisers to assist the company in the appointment of world-wide distribution partners. Once appointed all marketing and marketing aspects of MED3000 including launch will be handled by them. Futura's breakthrough, topical gel formulation MED3000 will become the first pan-European topical treatment for erectile dysfunction ("ED") available without the need of a doctor's prescription.
We are currently targeting initial launches in Europe in H1 2023.
MED3000 is currently not available for purchase.
As previously announced, following a number of meetings with the US Food and Drug Administration (FDA) the FDA agreed that an application may be made for MED3000 as a medical device for ED treatment, with a De Novo classification. A number of pre-submissions meeting with the FDA took place to define and confirm the detail of the work required for OTC classification in the USA for MED3000.
Data from a confirmatory clinical study, FM71, announced in August 2022, alongside additional data from previously announced FM57, supports the US regulatory submission for MED3000 with an application for OTC designation. The dossier is on track for submission at the end of September 2022.
US marketing authorisation of MED3000 by the FDA remains on course for Q1 2023.
We don’t anticipate needing to complete any further trials to obtain FDA granting marketing authorisation
The approval of MED3000 from the EU Notified Body (as announced on Friday 30th April) paves the way for rapid approval in many countries around the world, including in the Middle East, Africa, the Far East Latin American and Australia regions which allow “fast-track” review based on recognition of the EU CE mark. Due to post-Brexit arrangements, the EU CE mark can be used to market the product in Great Britain until 30 June 2023 by which time a specific UKCA mark has to be obtained. This will be a streamlined process since it is understood the UK application can bridge to the EU approval. Depending on the country these approvals are likely to take between 6 and 12 months from the time of submission.
In 2021 Futura signed three commercial deals:
March 2021: Co-High Investment Management to commercialise MED3000 in China and South East Asia.
August 2021: m8 Pharmaceuticals to commercialise MED3000 in Brazil and Mexico.
September 2021: Labatec Pharma to commercialise MED30 00 in the Gulf and Middle East Region.
In 2022, Futura entered into the following commercial deals:
March 2022: A. Menarini Korea Limited for the exclusive rights to MED3000 in South Korea.
May 2022: Cooper Consumer Health to commercialise MED3000 throughout the European Economic Area, United Kingdom and Switzerland.
All distribution will be handled by our appointed distribution partners and retailers. MED3000 addresses the significant and specific medical needs of men who suffer from erectile dysfunction and its use, where approved to be a treatment without the need for a doctor’s prescription, will require careful consideration by the patient in terms of self-diagnosis and use according to product label information.
EROXON™ is a gel that is a clinically proven treatment for erectile dysfunction and helps give adult men an erection within 10 minutes. Eroxon™ is also available without the need of a doctor’s prescription.
Futura has granted Cooper Consumer Health SAS (“Cooper”) exclusive marketing and distribution rights for Eroxon™ throughout the European Economic Area including the United Kingdom and Switzerland. All product or sales enquiries will be handled directly by Cooper including professional samples that may be available to healthcare practitioners.
Contact details can be found at www.cooperconsumerhealth.eu/
At this time we have not tested the product in patients who have undergone radical prostatectomy although the product has been shown to be effective in mild, moderate and severe ED of mixed causes.
If you have a medical condition you may need to speak to a doctor to discuss your condition to see if the product is suitable for you to use.
MED3000 will come with a leaflet part of which will cover warning and precautions and recommend users have a check-up with your doctor as soon as possible within the first 6 months of using MED3000 to ensure that any erection problems are not caused by another serious health condition.
We anticipate an initial shelf life of 2 years, extended to 3 years when the company generate longer term data.
The final price has yet to determine however market research supports a single dose price in the region of £5.00
We have not conducted studies on MED3000 in combination with PDE5i’s and it is not included on our proposed label. It is likely that a post-approval study will be needed to demonstrate synergy. We do not anticipate any safety issues in combining the two treatments Regulatory status in other geographies, especially where there are commercialisation agreements in place e.g. China, LatAm, Gulf States